Clinicopathologic Significance of Excision Repair Cross-Complementation 1 Expression in Patients Treated With Breast-Conserving Surgery and Radiation Therapy

Journal Article · Mon Mar 01 04:00:00 EST 2010 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2009.02.050· OSTI ID:21372087

Goyal, Sharad ^[1]; Parikh, Rahul R; Green, Camille; Schiff, Devora B.S. ^[2]; Moran, Meena S ^[3]; Qifeng, Yang ^[2]; Haffty, Bruce G ^[1]

---

1. Department of Radiation Oncology, Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ (United States)
2. Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ (United States)
3. Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (United States)

Purpose: The excision repair cross-complementation 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy in cancers of the head and neck and the lung. The purpose of this study was to evaluate the clinicopathologic and prognostic significance of ERCC1 expression in a cohort of early-stage breast cancer patients treated with breast conservation therapy. Methods and Materials: Paraffin specimens from 504 women with early-stage breast cancer treated with breast conservation therapy were constructed into tissue microarrays. The array was stained for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) and ERCC1. This was then correlated with clinicopathologic factors and outcomes data. Results: ERCC-1 expression was evaluable in 366 cases (72%). In this group, 32% and 38% of patients received adjuvant chemotherapy and hormonal therapy, respectively. Increased ERCC-1 expression was found to be correlated with ER positivity (p < 0.005), lower T stage (p < 0.017), nodal negativity (p < 0.013), age >50 (p < 0.006), reduced use of adjuvant chemotherapy (p < 0.02), and increased use of adjuvant hormonal therapy (p < 0.004). ERCC1 expression did not correlate with locoregional recurrence-free survival, distant metastasis-free survival, cause-specific survival, or overall survival. In patients who were both ERCC1-negative and -positive, the use of chemotherapy predicted for worse distant metastasis-free survival (p = 0.05 and p = 0.07, respectively) but not cause-specific survival or overall survival. Conclusions: Although ERCC1 expression did not predict for outcome measures in this dataset, overexpression correlated with favorable prognostic factors such as ER positivity, lower T stage, nodal negativity, and age >50. To our knowledge, this is the first study investigating ERCC1 expression in patients receiving adjuvant radiation therapy for breast cancer.

• OSTI ID: 21372087
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 3 Vol. 76; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BIOLOGICAL RECOVERY
BIOLOGICAL REPAIR
BODY
CHEMOTHERAPY
DISEASES
DNA REPAIR
ENZYMES
ESTROGENS
EXCISION REPAIR
GLANDS
GROWTH FACTORS
HEAD
HORMONES
KETONES
LUNGS
MAMMARY GLANDS
MEDICINE
MEMBRANE PROTEINS
MITOGENS
NECK
NEOPLASMS
NUCLEAR MEDICINE
NUCLEOTIDES
ORGANIC COMPOUNDS
ORGANS
PREGNANES
PROGESTERONE
PROTEINS
RADIOLOGY
RADIOTHERAPY
RECEPTORS
REPAIR
RESPIRATORY SYSTEM
STEROID HORMONES
STEROIDS
SURGERY
THERAPY